Aegros

WHO WE ARE

Mission

our mission

To develop & deliver the best hyperimmunes to protect against existing and emerging diseases. Aegros will achieve this by integrating its multi patent pending ElectroSeparation technology with existing processes to deliver safe & affordable therapeutic plasma products.

Short Story

About aEGROS

Aegros is Latin for ‘Patient’. We chose this name because it speaks to our focus on the patient. Every day we strive to place the patient first by providing therapeutic plasma products they would not otherwise be able to access.

At Aegros we believe access to life saving therapeutic plasma drugs is a human right and not a privilege. In a nutshell our mission is to put the patients first through innovation.

Over 30 years we have developed our ElectroSeparation process which enables countries to turn human plasma they collect into life saving hyperimmune products.

The first of these products is Covimmune™, a hyperimmune which will provided our frontline healthcare workers with protection against Covid-19.

AEGROS BOARD of DIRECTORS

Dr Nair graduated with honours in Physiology and Medicine from the University of Aberdeen and has a PhD in Medicine and Clinical Science from the Australian National University with specialty in cardiovascular medicine and haematology. Dr Nair has received a number of awards from international organisations including being specially recognised for his role in coagulation research by the Australian Capital Territory government. He has run biotechnology companies in Australia, the US and Singapore. Dr Nair has been heavily involved in mergers and acquisitions especially in the US and Europe and has US financial experience. Dr Nair’s corporate experience includes financial raisings, corporate public relations and organisational integration strategies, Human Resources, IP strategy and management, financial management and Research and Development. Dr Nair is an international expert in Coagulation Science with a special emphasis on fibrinogen. Dr Nair is the author of over 100 research publications and has had over 50 patents on various aspects of electrophoretic plasma separation technologies, including the CyMES  and their applications in both plasma protein separations, renal dialysis and cellular separations. He discovered the use of nano carbon particles in the radiographic imaging of blood clots. Dr Nair is the principal inventor of the CyMES  having developed and patented the plasma protein fractionation applications in the late 1990s to early 2000s. Dr Nair together with Mr John Manusu also ran the then world’s largest independent plasma collection organization based in the United States. This business collected both normal and specialty plasmas, including hyperimmunes for the US Government bioterrorism program. Dr Nair has served on the boards of a number of international biotechnology companies and US state Commercialisation Boards for Georgia, Florida and Alabama. Dr Nair and Mr Manusu recently received the first cGMP certification for a new plasma fractionation technology anywhere in the world for the last 40 years of the industry.

Mr Manusu has over 30 years experience running biotechnology companies worldwide. He has been involved in the development of the Aegros technology since its invention in 1985. Mr Manusu was also involved in the US plasma collection business creating, along with Dr Nair, the then world’s largest independent plasma collection organisation. This business collected both normal and specialty plasmas, including hyperimmunes for the US Government bioterrorism program. Throughout this period he has undertaken a number of significant cross border restructures, mergers, acquisitions and divestures. Finally, Mr Manusu has raised over $200 million in public funding and government R&D grants. Mr Manusu has a degree in Commerce and is a Fellow of the Financial Services Institute of Australasia. Mr Manusu has worked in the Australian, Asian and U.S. Biotechnology markets and is best described as a biotechnology entrepreneur.

Ms. Janet Bowen has almost 30 years of experience in the areas of sterile pharmaceuticals, biopharmaceuticals, oral solid dosages, and medical devices. During her career, she has held management positions in quality, regulatory, compliance, batch/lot release, and compliance/regulatory consulting. Ms. Bowen has worked for Sterling Drug, Sanofi, Abbott Laboratories, CAI Consulting, and PrIME Biologics prior to joining Aegros.  She hosted numerous successful inspections from the FDA, EMA, CMDA, TGA, Health Canada. While she was with Sterling Drug and Abbott, the sites received approval of 30 plus new products over five (5) year time span.  Many of them were generic drugs approved based on the data in the product dossier and without an onsite inspection. She has prepared companies for many different agency inspections, setting up quality systems, and to prepare the associated submissions. Ms. Bowen is knowledgeable in the requirements of FDA, HSA, EMA, CFDA, PMDA, TGA, and Health Canada, as well as other agencies. During her time in the industry, she has successfully registered over 50 products with the US FDA, EMA, TGA, HSA, and Canada. Ms. Bowen has a B.S. in Chemistry and a B. S. in Business Management. During her career, she has given presentations on Process Validation, Inspection Readiness, Combination Products, Quality by Design, and Aseptic Processing as well as others. She is a member of ISPE, PDA, ASQ, RAPS and is an active member of several regulatory Interest Groups within these organizations.

Andrew is a highly experienced solicitor.  He specialises in corporate and commercial law with a focus on initial public offerings and capital raising for both listed and unlisted companies.  Andrew has listed over 20 companies in a wide range of industries including mining, stockbroking, toll-roads, education, manufacturing and software.  Andrew also acts as Company Secretary for several listed and unlisted companies and is the representative of a nominated adviser on the NSX.  Andrew is a Director of IUOPay Limited ( ASX:IOU) and several unlisted public companies in the mining, mining services and health spaces. Andrew holds a BComm/LLB from the University of New South Wales.

Lord Wellesley is a highly experienced banking and capital markets executive with Board and not-for-profit expertise, comprising three decades of senior roles within tier-one institutions in London, Hong Kong and New York. At present Christopher serves on the Boards of AuStar Gold, an ASX quoted company, and Koch Metals in Australia. In addition he founded and runs the Skye Wellesley Foundation, a charity funding research into a cure for Rett Syndrome. He has an extensive network of senior, key relationships across the UK capital markets as well as demonstrating capital raising, corporate and financial markets expertise and a deep commitment to a range of private philanthropic activities.

AEGROS LEADERSHIP TEAM

Dr Nair graduated with honours in Physiology and Medicine from the University of Aberdeen and has a PhD in Medicine and Clinical Science from the Australian National University with specialty in cardiovascular medicine and haematology. Dr Nair has received a number of awards from international organisations including being specially recognised for his role in coagulation research by the Australian Capital Territory government. He has run biotechnology companies in Australia, the US and Singapore. Dr Nair has been heavily involved in mergers and acquisitions especially in the US and Europe and has US financial experience. Dr Nair’s corporate experience includes financial raisings, corporate public relations and organisational integration strategies, Human Resources, IP strategy and management, financial management and Research and Development. Dr Nair is an international expert in Coagulation Science with a special emphasis on fibrinogen. Dr Nair is the author of over 100 research publications and has had over 50 patents on various aspects of electrophoretic plasma separation technologies, including the CyMES  and their applications in both plasma protein separations, renal dialysis and cellular separations. He discovered the use of nano carbon particles in the radiographic imaging of blood clots. Dr Nair is the principal inventor of the CyMES  having developed and patented the plasma protein fractionation applications in the late 1990s to early 2000s. Dr Nair together with Mr John Manusu also ran the then world’s largest independent plasma collection organization based in the United States. This business collected both normal and specialty plasmas, including hyperimmunes for the US Government bioterrorism program. Dr Nair has served on the boards of a number of international biotechnology companies and US state Commercialisation Boards for Georgia, Florida and Alabama. Dr Nair and Mr Manusu recently received the first cGMP certification for a new plasma fractionation technology anywhere in the world for the last 40 years of the industry.

Mr Manusu has over 30 years experience running biotechnology companies worldwide. He has been involved in the development of the Aegros technology since its invention in 1985. Mr Manusu was also involved in the US plasma collection business creating, along with Dr Nair, the then world’s largest independent plasma collection organisation. This business collected both normal and specialty plasmas, including hyperimmunes for the US Government bioterrorism program. Throughout this period he has undertaken a number of significant cross border restructures, mergers, acquisitions and divestures. Finally, Mr Manusu has raised over $200 million in public funding and government R&D grants. Mr Manusu has a degree in Commerce and is a Fellow of the Financial Services Institute of Australasia. Mr Manusu has worked in the Australian, Asian and U.S. Biotechnology markets and is best described as a biotechnology entrepreneur.

Ms. Janet Bowen has almost 30 years of experience in the areas of sterile pharmaceuticals, biopharmaceuticals, oral solid dosages, and medical devices. During her career, she has held management positions in quality, regulatory, compliance, batch/lot release, and compliance/regulatory consulting. Ms. Bowen has worked for Sterling Drug, Sanofi, Abbott Laboratories, CAI Consulting, and PrIME Biologics prior to joining Aegros.  She hosted numerous successful inspections from the FDA, EMA, CMDA, TGA, Health Canada. While she was with Sterling Drug and Abbott, the sites received approval of 30 plus new products over five (5) year time span.  Many of them were generic drugs approved based on the data in the product dossier and without an onsite inspection. She has prepared companies for many different agency inspections, setting up quality systems, and to prepare the associated submissions. Ms. Bowen is knowledgeable in the requirements of FDA, HSA, EMA, CFDA, PMDA, TGA, and Health Canada, as well as other agencies. During her time in the industry, she has successfully registered over 50 products with the US FDA, EMA, TGA, HSA, and Canada. Ms. Bowen has a B.S. in Chemistry and a B. S. in Business Management. During her career, she has given presentations on Process Validation, Inspection Readiness, Combination Products, Quality by Design, and Aseptic Processing as well as others. She is a member of ISPE, PDA, ASQ, RAPS and is an active member of several regulatory Interest Groups within these organizations.

Leighton Hopper is Aegros’ CFO and COO and has both a Honours degree in Organic Chemistry and a MBA in Strategy Innovation. Mr. Hopper’s background includes senior management positions both in Australia and internationally in the pharmaceutical, chemical & FMCG industries including CPSA, Univar, Selleys and Dulux. He was the CEO and CFO of CPSA, recently acquired by Aegros and has experience in the management of finance, strategic funding, working capital, supply chain & operations.

Professor Albert Farrugia is an internationally recognised medical scientist in the field of biotherapeutics. He has been active in this area for forty years, including working for CSL, TGA and advising Governments. He has engaged in research, regulatory and clinical aspects in several countries. He has contributed widely to the peer-reviewed medical and scientific literature, with over 170 publications including 130 papers listed in PubMed. His interests include the development of strategic directions for the generation and clinical implementation of novel therapies, the use of health technology assessment in assisting health policy and the furtherance of advocacy for patients with rare diseases. He holds a Bachelor’s degree from the University of Malta and a PhD from the University of Edinburgh. In 2009 he was awarded the Ruth Sanger Oration Medal for services to blood transfusion in the Australian and Asia Pacific regions.

Dr Guy Gavagna – Chief Medical Officer

Dr. Guy Gavagna commenced his career as an emergency department medical officer within NSW Health. He subsequently obtained postgraduate qualifications in drug development and an MBA from the Australian Graduate School of Management. He has since gained broad therapeutic area experience in drug development over 20 years within the pharmaceutical industry, leading and developing high performing medical teams at several global biopharmaceutical companies.

Guy’s areas of expertise are in medical affairs, clinical research, and market access. He has a strong track record of delivering medical outcomes to ensure the successful launch of multiple innovative medicines; most recently he re-established a large affiliate of a multinational within the oncology therapeutic area, prior to that he successfully launched the local subsidiary of an emerging biopharma in rare diseases.

Guy has served on the executive of the Australian Pharmaceutical Physicians Association (APPA), on the Australian Prescriber Advisory Editorial Panel, and was for many years a lecturer in Pharmaceutical Medicine & Drug Development at UNSW.

SCIENTIFIC ADVISORY COMMITTEE

Professor Albert Farrugia is an internationally recognised medical scientist in the field of biotherapeutics. He has been active in this area for forty years, including working for CSL, TGA and advising Governments. He has engaged in research, regulatory and clinical aspects in several countries. He has contributed widely to the peer-reviewed medical and scientific literature, with over 170 publications including 130 papers listed in PubMed. His interests include the development of strategic directions for the generation and clinical implementation of novel therapies, the use of health technology assessment in assisting health policy and the furtherance of advocacy for patients with rare diseases. He holds a Bachelor’s degree from the University of Malta and a PhD from the University of Edinburgh. In 2009 he was awarded the Ruth Sanger Oration Medal for services to blood transfusion in the Australian and Asia Pacific regions.

Kailing Wang obtained her PhD in biochemistry at the University of Sydney in 1997, followed by post-doctoral training at the University of Sydney and the Victor Chang Cardiac Research Institute. She has over 25 years of medical research experience in the field of protein biochemistry, molecular biology, cell biology and virology. She worked for Gradipore/ Life Therapeutics from 2000 till 2006 and NuSep/ PrIME Biologics from 2011 to 2017 before joining Aegros. She has accumulated extensive hands-on R&D experience in membrane electrophoresis technology development, application development and viral/TSE clearance studies in plasma fractionation. At Sydney University Dr Wang was a Business Development Manager responsible for developing commercialisation opportunities across the research translation continuum. Dr Wang is the co-inventor of the CyMES and has authored a number of papers & patents with Dr Nair. Dr Wang was the Chief Scientific Officer in PrIME and was a significant contributor to establishing cGMP certification for the first time for a new plasma fractionation technology over the past 40 years.

Professor Stephen Mahler is Director of the Australian Research Council (ARC) Training Centre for Biopharmaceutical Innovation and Deputy Director of the National Biologics Facility, Queensland Node.  He is also a Senior Group Leader at the Australian Institute for Bioengineering and Nanotechnology (AIBN), and Professor (continuing appointment) in the School of Chemical Engineering, The University of Queensland.  He has been involved in the research and development of biologic medicines for over 25 years.  He was appointed to his current position at the AIBN in January, 2007.